Çiğdem YILMAZ, Erkan ÖZCENGİZ, Gülay ÖZCENGİZ

Recombinant outer membrane protein Q and putative lipoprotein from Bordetella pertussis inducing strong humoral response were not protective alone in the murine lung colonization model

Öz Despite high vaccination coverage after introduction of whole cell (wP) and acellular pertussis (aP) vaccines, pertussis resurgence has been reported in many countries. aP vaccines are commonly preferred due to side effects of wP vaccines and formulated with aluminum hydroxide (Alum), which is not an effective adjuvant to eliminate Bordetella pertussis. Low efficiency of current aP vaccines is thought to be the main reason for the resurgence for which newer generation aP vaccines are needed. In the present study, immunogenicity and protective efficacy of outer membrane protein Q (OmpQ) and a putative lipoprotein (Lpp) from B. pertussis were investigated in mice by using two different adjuvants, monophosphoryl lipid A (MPLA) or Alum. OmpQ and putative Lpp were cloned, expressed, and purified from Escherichia coli. The proteins were formulated to immunize mice. Both recombinant OmpQ and putative Lpp induced a significant increase in immunoglobulin G1 (IgG1) and immunoglobulin G2a (IgG2a) responses compared to the control group. Moreover, MPLA-adjuvanted formulations resulted in higher IgG2a levels than Alum-adjuvanted ones. However, there were no significant differences between test and control groups regarding interferon-gamma (IFN-γ) levels, and the mice lung colonization experiments indicated that neither rOmpQ nor rLpp could confer protection alone against B . pertussis challenge.

Anahtar Kelimeler:

Adjuvants, Bordetella pertussis, pertussis vaccines, recombinant proteins

PDF

___

Allen AC, Mills KHG (2014). Improved pertussis vaccines based on adjuvant that induce cell-mediated immunity. Expert Rev Vaccines 13: 1253-1264.

Altındiş E, Tefon BE, Yıldırım V, Özcengiz E, Becher D, Hecker M, Özcengiz G (2009). Immunoproteomic analysis of Bordetella pertussis and identification of new immunogenic proteins. Vaccine 27: 542-548.

Barnard A, Mahon BP, Watkins J, Redhead K, Mills KHG (1996). Th1/Th2 cell dichotomy in acquired immunity to Bordetella pertussis : variables in the in vivo priming and in vitro cytokine detection techniques affect the classification of T-cell subsets as Th1, Th2 or Th0. Immunology 87: 372-380.

Burns DL, Meade BD, Messionnier NE (2014). Pertussis resurgence: perspectives from the working group meeting on pertussis on the causes, possible paths forward, and gaps in our knowledge. J Infect Dis 209: S32-S35.

CDC (2014). Pertussis epidemic - California, 2014. MMWR-Morbid Mortal W 63: 1129-1132.

Chiappini E, Stival A, Galli L, de Martino M (2015). Pertussis re- emergence in the post-vaccination era. BMC Infect Dis 13: 151.

de Gouw D, O’Serra D, de Jonge MI, Hermans PWM, Wessels HJCT, Zomer A, Yantorno OM, Diavatopoulos DA, Mooi FR (2014). The vaccine potential of Bordetella pertussis biofilm-derived membrane proteins. Emerg Microbes Infec 3: e58.

Edwards KM (2014). Review of the laboratory approaches to the detection of antibody and cell-mediated immunity to pertussis disease and vaccine. Expert Rev Vaccines 13: 1183-1190.

Edwards KM, Berbers GA (2014). Immune responses to pertussis vaccines and disease. J Infect Dis 209: S10-S15.

Edwards KM, Meade BD, Decker MD, Reed GF, Rennels MB, Steinhoff MC, Anderson EL, Englund JA, Pichichero ME, Deloria MA (1995). Comparison of 13 acellular pertussis vaccines: overview and serologic responses. Pediatrics 96: 548- 557.

Fedel G, Cassone A, Ausiello CM (2015). T-cell immune responses to Bordetella pertussis infection and vaccination. Pathog Dis 73: ftv051.

Feng S, Barthold SW, Telford SR, Fikrig E (1996). P55, an immunogenic but nonprotective 55-Kilodalton Borrelia burgdorferi protein in murine Lyme disease. Infect Immun 64: 363-365.

Finger H, von Koenig CHW (1996). Bordetella . In: Baron S, editor. Medical Microbiology. 4th ed. Galveston, TX, USA: University of Texas Medical Branch at Galveston. Finkelman FD, Katona IM, Mosmann TR, Coffman RL (1988). IFN-gamma regulates the isotype of Ig secreted during in vivo humoral immune responses. J Immunol 140: 1022-1027.

Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, Ooi P, Smith RP, Weise P, Wetherell M et al (2004). Vaccine potential of the Neisseria meningiditis 2086 lipoprotein. Infect Immun 72: 2088-2100.

Gigliotti F, Wiley JA, Harmsen AG (1998). Immunization with Pneumocystis carinii gpA is immunogenic but not protective in a mouse model of P . c arinii pneumonia. Infect Immun 66: 3179-3182.

Guan Q, Wang X, Wang X, Teng D, Mao R, Zhang Y, Wang J (2015). Recombinant outer membrane protein A induces a protective immune response against Escherichia coli infection in mice. Appl Microbiol Biotechnol 99: 5451-5460.

Hayes JA, Erben E, Lamberti Y, Ayala M, Maschi F, Carbone C, Gatti B, Parisi G, Rodriguez ME (2011). Identification of a new protective antigen of Bordetella pertussis . Vaccine 29: 8731- 8739.

Hayes JA, Erben E, Lamberti Y, Principi G, Maschi F, Ayala M, Rodrigues ME (2013). Bordetella pertussis iron regulated proteins as potential vaccine components. Vaccine 31: 3543- 3548.

Hewlett EL, Burns DL, Cotter PA, Harvill ET, Merkel TJ, Quinn CP, Stibitz ES (2014). Pertussis pathogenesis – what we know and what we don’t know. J Infect Dis 209: 982-985. Higgs R, Higgins SC, Ross PJ, Mills KGH (2012). Immunity to the respiratory pathogen Bordetella pertussis . Mucosal Immunol 5: 485-500.

Hinode D, Nakamura R, Grenier D, Mayrand D (1998). Cross- reactivity of specific antibodies directed to heat shock proteins from periodontopathogenic bacteria and of human origin. Oral Microbiol Immunol 13: 55-58.

King AJ, Berbers G, van Oirschot HFLM, Hoogerhout P, Knipping K, Mooi FR (2001). Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity. Microbiology 147: 2885-2895.

Lam C, Octavia S, Bahrame Z, Sintchenko V, Gilbert GL, Lan R (2012). Selection and emergence of pertussis toxin promoter ptxP3 allele in the evolution of Bordetella pertussis . Infect Genet Evol 12: 492-495.

Maleki F, Khosravi A, Nasser A, Taghinejad H, Azizian M (2016). Bacterial heat shock protein activity. J Clin Diagn Res 10: BE01-BE03.

Mansouri E, Gabelsberger J, Knapp B, Hundt E, Lenz U, Hungerer KD, Gilleland HE, Staczek J, Domdey H, von Specht BU (1999). Safety and immunogenicity of a Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers. Infect Immun 67: 1461-1470.

Marr N, Oliver DC, Laurent V, Poolman J, Denoel P, Fernandez RC (2008). Protective activity of the Bordetella pertussis BrkA autotransporter in the murine lung colonization model. Vaccine 26: 4306-4311.

McKee AS, Munks MW, Marrack P (2007). How do adjuvants work? Important considerations for new generation adjuvants. Immunity 27: 687-690.

Mooi FR, He Q, Guiso N (2007). Phylogeny, evolution, and epidemiology of Bordetellae . In: Locht C, editor. Bordetella : Molecular Microbiology. Norfolk, UK: Horizon Bioscience, pp. 17-45.

Mooi FR, van Loo IHM, van Gent M, He Q, Bart MJ, Heuvelman KJ, de Greeff SC, Diavatopoulos D, Teunis P, Nagelkerke N et al. (2009). Bordetella pertussis strains with increased toxin production associated with pertussis resurgence. Emerg Infect Dis 15: 1206-1213.

Mooi FR, van Oirschot HFLM, Heuvelman K, van der Heide HGJ, Gaastra W, Willems JL (1998). Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in the Netherlands: temporal trends and evidence for vaccine- driven evolution. Infect Immun 66: 670-675.

Okay S, Özcengiz E, Gürsel İ, Özcengiz G (2012). Immunogenicity and protective efficacy of the recombinant Pasteurella lipoprotein E and outer membrane protein H from Pasteurella multocida A:3 in mice. Res Vet Sci 93: 1261-1265.

Ramagli LS, Rodriguez LV (1985). Quantitation of microgram amounts of protein in two-dimensional polyacrylamide gel electrophoresis sample buffer. Electrophoresis 6: 559-563.

Ross PJ, Sutton CE, Higgins S, Allen AC, Walsh K, Misiak A, Lavelle EC, McLoughlin RM, Mills KH (2013). Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis : towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog 9: e1003264.

Ryder AB, Tollefson SJ, Podsiad AB, Johnson JE, Williams JV (2010). Soluble recombinant human metapneumovirus G protein is immunogenic but not protective. Vaccine 28: 4145-4152.

Sealey KL, Harris SR, Fry NK, Hurst LD, Gorringe AR, Parkhill J, Preston A (2015). Genomic analysis of isolates from the United Kingdom 2012 pertussis outbreak reveals that vaccine antigen genes are unusually fast evolving. J Infect Dis 212: 294-301.

Sealey KL, Belcher T, Preston A (2016). Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect Genet Evol 40: 136-143.

Tefon BE, Maaß S, Özcengiz E, Becher D, Hecker M, Özcengiz G (2011). A comprehensive analysis of Bordetella pertussis surface proteome and identification of new immunogenic proteins. Vaccine 29: 3583-3595.

Tefon BE, Özcengiz E, Özcengiz G (2013). Pertussis vaccines: state- of-the-art and future trends. Curr Topics Medic Chem 13: 2581-2596.

Warfel JM, Edwards KM (2015). Pertussis vaccines and the challenge of inducing durable immunity. Curr Opin Immunol 35: 48-54.

WHO (2017). WHO Vaccine-Preventable Diseases: Monitoring System. 2017 Global Summary. Geneva, Switzerland: WHO, 2017.

Wu JR, Shien JH, Shieh HK, Chen CF, Chang PC (2007). Protective immunity conferred by recombinant Pasteurella multocida lipoprotein E (PlpE). Vaccine 25: 4140-4148.

Xing D, Asokanathan C, Xu YH, Bolgiano B, Douglas-Bardsley A, Zhang S, Wang J, Corbel M (2014). Relationship of immunogenicity to protective potency in acellular pertussis vaccines. Hum Vaccin Immunother 10: 2066-2073.

Xu Y, Liu B, Gröndahl-Yli-Hannuksila K, Tan Y, Feng L, Kallonen T, Wang L, Peng D, He Q, Wang L et al. (2015). Whole-genome sequencing reveals the effect of vaccination on the evolution of Bordetella pertussis . Sci Rep 5: 12888.

Yılmaz Ç, Aycan A, Özcengiz E, Özcengiz G (2016). Immunogenicity and protective efficacy of recombinant iron superoxide dismutase protein from Bordetella pertussis in mice models. Microbiol Immunol 60: 717-724.